Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2001
Business Overview: A worldwide developer, manufacturer, and marketer of medical devices for less invasive procedures, operating in four geographic segments: United States, Europe, Japan, and Inter-Continental.
Key Financial Metrics
| Metric (in millions) | Q2 2001 | Q2 2000 | 6 Months 2001 | 6 Months 2000 |
|---|---|---|---|---|
| Net Sales | $672 | $695 | $1,326 | $1,374 |
| Gross Profit | $404 | $478 | $836 | $944 |
| Gross Margin % | 60.1% | 68.8% | 63.0% | 68.7% |
| Operating Income (Loss) | $(150) | $182 | $(110) | $351 |
| Net Income (Loss) | $(172) | $122 | $(177) | $228 |
| Diluted EPS | $(0.43) | $0.30 | $(0.44) | $0.55 |
| Cash from Operations (6mo) | $214 | $384 | $214 | $384 |
| Cash & Equivalents (End Period) | $55 | $54 | $55 | $54 |
| Total Debt (Short + Long Term) | $1,124 | $778 | $1,124 | $778 |
Note: Debt figures include Commercial Paper ($56M), Bank Obligations ($556M), and Long-term Debt ($568M) as of June 30, 2001.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 3% year-over-year for both the quarter and the six-month period. This was primarily driven by a $29 million (quarter) and $53 million (six-month) adverse impact from foreign currency fluctuations and decreased sales of coronary stents and balloons.
- Significant Losses: The company reported a net loss of $172 million for the quarter and $177 million for the six months, compared to net income of $122 million and $228 million in the prior year periods.
- Major Charges: The loss was driven by non-recurring and strategic charges:
- Purchased R&D: $188 million (Q2) and $267 million (6 months) related to acquisitions (Interventional Technologies, Embolic Protection, Catheter Innovations, Quanam).
- Inventory Provision: $49 million charge for excess NIR(R) coronary stent inventory due to declining demand for current technology.
- Intangible Write-downs: $24 million write-down of discontinued R&D programs.
- Restructuring: $19 million (Q2) and $32 million (6 months) associated with the global operations plan.
- Margin Compression: Gross margin declined significantly due to the inventory provision and global operations plan costs, partially offset by operational improvements.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook
- Global Operations Plan: The company expects to achieve pre-tax operating savings of approximately $100 million in 2001, $220 million in 2002, and $250 million annually thereafter relative to a 1999 base. Incremental savings for 2001 are estimated at $30 million.
- Capital Expenditures: Expected to be approximately $50 million for the remainder of 2001.
- Acquisitions: Completed acquisitions of IVT, EPI, CI, and Quanam. Announced acquisition of Cardiac Pathways Corporation (CPC) for approximately $115 million (consummated August 9, 2001).
- Product Strategy: Launched the Maverick(R) Balloon Dilatation Catheter. Future growth depends on the successful development and regulatory approval of next-generation stent platforms.
Risks and Contingencies
- Medinol Litigation: Medinol Ltd., the exclusive supplier of NIR(R) stents, sued the company alleging fraud and breach of contract, seeking to end the distribution relationship. The company has countersued. This poses a significant supply chain risk.
- Patent Litigation:
- Cordis (J&J): A jury found the NIR(R) stent infringed one Cordis patent, awarding approximately $324 million in damages. Judgment has not been entered; the company plans to appeal. Potential exposure is estimated at $324 million plus interest and future damages.
- Medtronic AVE: An arbitration panel awarded the company $169 million in damages for patent infringement by Medtronic AVE. The company is seeking court confirmation.
- Regulatory and Market Risks: Volatility in the coronary stent market, delays in FDA approvals for new products, and pressure from managed care on pricing.
- Liquidity: Working capital turned negative ($131 million deficit) due to short-term borrowings used to fund acquisitions. The company has $1.6 billion in revolving credit facilities and expects to refinance a $600 million facility in Q3 2001.
Investor Verification Checklist
- Medinol Supply Chain: Verify the status of the litigation with Medinol and the company's ability to secure NIR(R) stent supply or transition to alternative suppliers.
- Cordis Litigation Outcome: Monitor the final judgment and appeal status regarding the $324 million patent infringement award.
- Inventory Levels: Track the reduction of excess NIR(R) stent inventory and the impact on future gross margins.
- Debt Refinancing: Confirm the successful refinancing of the $600 million 364-day credit facility expiring in September 2001.
- Acquisition Integration: Assess the integration progress of IVT, EPI, CI, Quanam, and CPC, and the realization of projected synergies.
- Product Launches: Monitor the regulatory approval timeline and market adoption of next-generation stent and balloon platforms.